PROJECT SUMMARY The overall goal of this program is to discover and develop small molecule orally bioavailable drugs to treat SARS-CoV2 and other viruses with pandemic potential. Our specific role is to provide a central core facility, with expertise and technologies that use high-throughput screening to identify potent and selective drug-like lead compounds and further characterize these compounds for concentration-response relationships, affinity, stoichiometry, off-rates, contributions of entropy and enthalpy of binding of the chosen molecular targets. We will also support testing in high-throughput phenotypic assays for anti-viral efficacy. We intend to work closely with the project leaders and medicinal chemists to rapidly gain critical information on the mechanism of action of various compounds derived from the chemical scaffolds identified in the screens conducted and to support medicinal chemistry programs in testing improved congeners for potency and selectivity against the primary targets.